Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN D.
CLARITIN HIVES RELIEF vs CLARITIN-D
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
FDA: Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, nasal pruritus, ocular pruritus) and chronic idiopathic urticaria.FDA: Relief of hives (urticaria) and itching.
Temporary relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, runny nose, itchy/watery eyes)Temporary relief of nasal congestion due to common cold, hay fever, or upper respiratory allergies
10 mg orally once daily
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Primarily hepatic via CYP3A4 and CYP2D6; forms active metabolite desloratadine.
Loratadine is extensively metabolized in the liver via CYP3A4 and CYP2D6 to its active metabolite descarboethoxyloratadine. Pseudoephedrine is partially metabolized in the liver by N-demethylation and undergoes renal excretion.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Loratadine: 97-99% to albumin and alpha-1-acid glycoprotein; desloratadine: 73-76%.
Loratadine: 97-99% (albumin, alpha-1-acid glycoprotein); desloratadine: 82-87%; pseudoephedrine: negligible (<5%).
Loratadine: 120 L/kg, indicating extensive tissue distribution; desloratadine: 40 L/kg.
Loratadine: 120 L/kg (extensive tissue distribution); desloratadine: 15-20 L/kg; pseudoephedrine: 2-3 L/kg (distributes into body water).
Oral: ~100% (loratadine is rapidly and well absorbed; first-pass metabolism to desloratadine reduces parent drug concentration but active metabolite contributes to effect).
Loratadine: ~40% (high first-pass metabolism); pseudoephedrine: ~100% (oral); desloratadine: ~40-50% (oral).
GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: 5 mg orally once daily
For GFR 30-50 mL/min: administer every 24 hours. For GFR <30 mL/min: contraindicated due to risk of pseudoephedrine accumulation.
Child-Pugh A: no adjustment; Child-Pugh B or C: 5 mg orally once daily
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: administer every 24 hours or consider alternative therapy.
6-11 years: 5 mg orally once daily; 12 years and older: 10 mg orally once daily
Children <12 years: not recommended due to fixed-dose combination. Children ≥12 years: same as adult dose.
No specific adjustment; use caution due to age-related renal impairment may require 5 mg once daily
Elderly patients (≥65 years): use with caution due to increased sensitivity to pseudoephedrine (e.g., CNS stimulation, hypertension); consider starting with lower dose or alternative therapy.
None.
Not available.
Caution in patients with hepatic or renal impairment; avoid use with alcohol or CNS depressants; may cause drowsiness or dizziness; use with caution in elderly patients.
Severe hypertension or coronary artery disease; increased intraocular pressure; glaucoma; prostatic hypertrophy; diabetes mellitus; thyroid disease; use in patients with renal or hepatic impairment; avoid use with MAOIs or within 14 days of stopping MAOIs; risk of cardiovascular events including stroke and arrhythmias.
Hypersensitivity to loratadine or any component; severe hepatic impairment; pediatric patients <6 years of age (for this product).
Hypersensitivity to loratadine, pseudoephedrine, or any component; narrow-angle glaucoma; severe hypertension; severe coronary artery disease; concurrent use or recent use of MAOIs (within 14 days); urinary retention; patients with severe hepatic impairment.
Data Pending Review
Data Pending Review
No significant food interactions; grapefruit juice does not affect loratadine metabolism. Avoid alcohol as it may potentiate CNS depression.
Avoid concurrent consumption of alcohol or caffeine-containing beverages (coffee, tea, cola) as they may exacerbate stimulant effects. Taking with food may reduce gastrointestinal irritation. Avoid high-tyramine foods (aged cheese, cured meats) if also taking MAOIs (contraindicated due to hypertensive crisis risk).
Loratadine is categorized as FDA Pregnancy Category B. Animal studies have not demonstrated fetal harm, but adequate, well-controlled studies in pregnant women are lacking. No known teratogenic risk in any trimester; however, first-trimester exposure should be with caution.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimester: Risk of premature labor, low birth weight, and neonatal withdrawal with chronic high-dose decongestant use.
Loratadine is excreted into breast milk; M/P ratio is approximately 1.17 for parent drug and 0.85 for active metabolite. Concentrations are low, and adverse effects in nursing infants are unlikely. Considered compatible with breastfeeding, but monitor infant for sedation or irritability.
Loratadine (antihistamine) and pseudoephedrine (decongestant) both excreted in breast milk. M/P ratio for loratadine is approximately 1.1; pseudoephedrine M/P ratio is approximately 2.6. Potential for irritability and decreased milk supply due to pseudoephedrine. Use with caution, preferably immediate-release loratadine alone.
No specific dose adjustment is required during pregnancy. Pharmacokinetic changes (increased plasma volume, altered hepatic metabolism) may reduce serum concentrations, but clinical efficacy is maintained with standard doses (10 mg once daily).
No standard dose adjustments for pregnancy. Pharmacokinetic changes (increased renal blood flow, decreased plasma protein binding) may alter drug clearance but no specific dose recommendations due to lack of data. Use lowest effective dose for shortest duration.
Category C
Category C
Loratadine is a second-generation antihistamine with minimal anticholinergic effects; onset of action within 1-3 hours, duration 24 hours; not effective for acute urticaria in some patients; may require dose adjustment in hepatic impairment (Child-Pugh class B or C).
CLARITIN-D combines loratadine (antihistamine) and pseudoephedrine (decongestant). Use with caution in hypertension, hyperthyroidism, and prostate hypertrophy. Avoid in severe coronary artery disease. Monitor for insomnia and nervousness. Onset of action within 1-3 hours, duration 12 hours. Extended-release formulation must not be crushed or chewed.
Take once daily with or without food.Do not exceed recommended dose; may cause drowsiness in some individuals.Avoid alcohol as it may increase drowsiness.If symptoms persist after 3 days, consult a healthcare provider.Not recommended for children under 6 years without medical advice.
Take exactly as directed; do not exceed 2 tablets in 24 hours.Swallow whole; do not crush or chew extended-release tablets.Avoid alcohol; may increase drowsiness or dizziness.Contact your doctor if symptoms persist beyond 7 days or with fever.Do not use with other decongestants or antihistamines without consulting a physician.May cause insomnia; take last dose at least 4-6 hours before bedtime.Inform your doctor if you have high blood pressure, heart disease, or prostate issues.